Leigh syndrome with cardiomyopathy

For MT-ATP6 m.8969G>A, a likely pathogenic variant affecting ATP synthase subunit 6 (complex V), small-molecule mitochondrial targeted therapies represent the primary pharmacological approach given the absence of gene therapy or editing tools capable of correcting mitochondrial-encoded genes in vivo at clinical scale. EPI-743 (vatiquinone), idebenone, and other electron transport chain bypass agents aim to improve residual mitochondrial function, reduce oxidative stress, and support cellular bioenergetics, though none directly corrects the genetic defect.

MT-ATP6 encodes subunit a of mitochondrial ATP synthase (complex V), which forms the proton channel that drives rotary catalysis for ATP production. Variants at this locus (most commonly m.8993T>G/C causing Leigh syndrome) disrupt proton translocation, causing impaired oxidative phosphorylation and cellular energy failure predominantly in high-energy-demand tissues (brain, heart, muscle). The m.8969G>A variant affects a conserved residue in the proton half-channel. EPI-743 (α-tocopherylquinone) acts as an electron carrier that bypasses dysfunctional complex I-III-IV by transferring electrons to oxidized glutathione, improving cellular redox balance. An open-label study showed stabilization or improvement in 11 of 13 children with genetically confirmed mitochondrial disease (Enns et al., Mol Genet Metab 2012; PMID:22424739). Idebenone (a CoQ10 analogue) can accept electrons from complex I and donate directly to complex III, partially bypassing the electron transport chain bottleneck. For MT-ATP6 specifically (complex V deficiency), the rationale is indirect: improving upstream ETC efficiency may partially compensate for reduced ATP synthase activity by increasing the mitochondrial membrane potential and supporting alternative ATP production pathways.

No small molecule directly repairs or replaces defective ATP synthase. EPI-743 and idebenone act on electron transport upstream of complex V — their mechanism is at best indirectly supportive for a primary ATP synthase defect, not a targeted therapy. Clinical trial data for mitochondrial disease therapies are plagued by small sample sizes, heterogeneous genotypes, and lack of placebo controls. The Phase 2 trial of EPI-743 in Leigh syndrome (NCT01370447) showed some benefit but was underpowered. Idebenone failed to meet primary endpoints in LHON Phase 3 (RHODOS trial) although post-hoc analyses showed benefit in early-stage patients. Heteroplasmy levels for m.8969G>A critically determine disease severity and potential drug responsiveness — patients with near-homoplasmic mutant loads may be beyond pharmacological rescue. Mitochondrial cardiomyopathy, the defining feature of this disease entry, may require cardiac-specific interventions (CoQ10, carnitine, and cardiac transplantation for refractory cases) beyond general mitochondrial support.

Base Editing (BE4max) via AAV9 delivery is a rationale-driven therapeutic strategy for Leigh syndrome with cardiomyopathy targeting the MT-ATP6 m.8993T>C variant (Pathogenic, transition). The editing system (BE4max (cytosine base editor)) converts the pathogenic C to T (or G to A on the target strand), restoring the wild-type codon. Target tissue: Heart. Therapeutic goal: Correct the m.8993T>G mutation in MT-ATP6 to normalize mitochondrial ATP synthase function and prevent Leigh syndrome with cardiomyopathy. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: MT-ATP6 NC_012920.1(MT-ATP6):m.8993T>C is classified as Pathogenic (ClinVar variation ID 9642). Molecular consequence: transition. 2. Epidemiology: Leigh syndrome (ORPHA:506) is a rare, early-onset mitochondrial encephalomyelopathy with an estimated birth prevalence around 1 in 36,000–40,000. Onset is typically in infancy (median ~7 months), and over half of patients die within the first few years of life. Cardiac involvement, particularly hype 3. Standard of care: There is no curative therapy for Leigh syndrome. Current management is largely supportive: nutritional and respiratory support, seizure control, management of movement disorders, and treatment of heart failure and arrhythmias when cardiomyopathy is present. Empiric use of vitamin and cofactor supple 4. Pipeline: Small-molecule and cofactor therapies: EPI-743/vatiquinone has completed Phase II and entered Phase III trials in inherited mitochondrial diseases including Leigh syndrome, but no disease-modifying approval exists. Additional agents (idebenone, KH176, rapamycin/mTOR inhibition, hypoxia-based approac 5. CBE clinical validation: BE4max (Koblan et al. 2018) is the gold-standard cytosine base editor. Multiple CBE programs are in clinical development for liver and hematologic targets.

1. No published data specifically correcting MT-ATP6 m.8993T>C with Base Editing (BE4max); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 4. Delivery to Heart tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments. 4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.